Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03920397
Recruitment Status : Enrolling by invitation
First Posted : April 18, 2019
Last Update Posted : April 23, 2019
Sponsor:
Information provided by (Responsible Party):
Débora Lopes Souto, Universidade Federal do Rio de Janeiro

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
In this prospective, dual-center, open trial, patients with recent onset type 1 diabetes will receive one dose of allogenic Adipose tissue-derived stromal/stem cells (1x106 cells/kg) and oral cholecalciferol 2000UI/day for 24 months (group 1). They will be compare to patients that will receive just oral cholecalciferol 2000UI/day (group 2) and standard treatment (group 3: no treatment). Adverse events will be record. In addition, glycated hemoglobin, insulin dose, frequency of hypoglycemia, glycemic variability, % of time in hyper and hypoglycemia and peak response of the C-peptide after the mixed meal teste wil be measure at baseline (T0), after 3 (T3), 6 (T6), 12 (T12), 18 (T18), and 24 (T24) months.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Mellitus Biological: Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation Not Applicable

  Show Detailed Description

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Patients with recent onset type 1 diabetes wil receive an dose of allogenic adipose tissue-derived stem/stromal cells (ASCs) and oral Cholecalciferol UI/day for 24 months.
Masking: None (Open Label)
Masking Description: This is a open trial study.
Primary Purpose: Treatment
Official Title: Allogenic Adipose Derived Mesenchymal Stem Cells and Vitamin D Supplementation in Patients With Recent-onset Type 1 Diabetes Mellitus
Actual Study Start Date : March 1, 2015
Estimated Primary Completion Date : March 1, 2020
Estimated Study Completion Date : December 1, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Adipose tissue-derived stem/stromal cells
Safety of adipose tissue-derived stem/stromal cells (ASCs) for 24 months in patients with recente onset type 1 diabetes.
 Biological: Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation
The investigators will acess area under the curve of C-peptide after a liquid mixed meal (Glucerna®), considering the time 0 (basal), 30, 60, 90 and 120 minutes in each follow-up outpatient visit (3 [T3], 6 [T6], 12 [T12], 18 [T18], and 24 [T24] months after the adipose tissue-derived stem/stromal cells infusion). Other Clinical and Pancreatic Function Evaluation that wil be assess are: Weight, height, body mass index (BMI), blood pressure, heart frequency, frequency of hypoglycemia and insulin dose/kg of body weight, blood count, lipids, renal and hepatic function, thyroid stimulating hormone, free tyroxine, antithyroglobulin antibody, calcium, phosphorus and 25-Hydroxy Vitamin D.
Experimental: Daily 2000 UI of daily oral cholecalciferol
To investigate the efficacy of daily 2000 UI Cholecalciferol/day for 24 months in patients with recente onset type 1 diabetes.
 Biological: Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation
The investigators will acess area under the curve of C-peptide after a liquid mixed meal (Glucerna®), considering the time 0 (basal), 30, 60, 90 and 120 minutes in each follow-up outpatient visit (3 [T3], 6 [T6], 12 [T12], 18 [T18], and 24 [T24] months after the adipose tissue-derived stem/stromal cells infusion). Other Clinical and Pancreatic Function Evaluation that wil be assess are: Weight, height, body mass index (BMI), blood pressure, heart frequency, frequency of hypoglycemia and insulin dose/kg of body weight, blood count, lipids, renal and hepatic function, thyroid stimulating hormone, free tyroxine, antithyroglobulin antibody, calcium, phosphorus and 25-Hydroxy Vitamin D.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Pancreatic β-cell function after an adipose tissue-derived stem/stromal cells infusion [ Time Frame: 24 months ]

    Thirth patients with recent-onset type 1 diabetes wil receive adipose tissue-derived stem/stromal cells (ASCs). The patients wil be admitte in the day of the infusion and wil discharge 24 hours after infusion. A single dose of ASCs wil be infuse in a peripheral upper arm vein during 15-20 minutes.

    Pancreatic β-cell function will be assess at each follow-up outpatient visit (1, 3, 6, 12, 18 and 24 months after the ASCs infusion). In each visit, C-Peptide wil be analyze by immunofluorometric assay, considering the time 0 (basal), and peak stimulated C-Peptide (30, 60, 90 and 120 minutes) after mixed meal test (Glucerna)


  2. Glycemic control after an adipose tissue-derived stem/stromal cells [ Time Frame: 24 months ]

    Thirth patients with recent-onset type 1 diabetes wil receive adipose tissue-derived stem/stromal cells (ASCs). The patients wil be admitte in the day of the infusion and wil discharge 24 hours after infusion. A single dose of ASCs wil be infuse in a peripheral upper arm vein during 15-20 minutes.

    Frequency of hypoglycemia (%) insulin dose/kg, and blood samples will be drawn for the Glycated hemoglobin assessment (High Performance Liquid Chromatography by boronate affinity) at each follow-up outpatient visit (1, 3, 6, 12, 18 and 24 months after the ASCs infusion)



Secondary Outcome Measures :
  1. Oral cholecalciferol 2000UI/day supplementation [ Time Frame: 24 months ]

    The same patients with recent-onset type 1 diabetes wil receive adipose tissue-derived stem/stromal cells (ASCs) will receive Oral cholecalciferol 2000UI/day supplementation for 24 months.

    The sérum 25-Hydroxy Vitamin D will be assess at each follow-up outpatient visit (1, 3, 6, 12, 18 and 24 months after the ASCs infusion) and C-Peptide wil be analyze by immunofluorometric assay, considering the time 0 (basal), and peak stimulated C-Peptide (30, 60, 90 and 120 minutes) after mixed meal test (Glucerna)



Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 35 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of Type 1 Diabetes according to the American Diabetes Association criteria for a period less than four months.
  • Pancreatic Autoimmunity (positive anti-glutamic acid decarboxylase [GAD]; and/or Islet antigen 2 [anti-IA2]).

Exclusion Criteria:

  • Clinical evidence of malignancy or prior history.
  • Pregnancy or desire to become pregnant within 12 months of the study.
  • Breastfeeding .
  • HIV(+), Hepatitis B (+), Hepatitis C(+).
  • Diabetic ketoacidosis at diagnosis.
  • Glomerular filtration rate less than 60ml/min.
  • Use of immunosuppressors or glucocorticoids.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03920397


Locations
Layout table for location information
Brazil
Clementino Fraga Filho University Hospital of Rio de Janeiro
Rio de Janeiro, Brazil, 21941-913
Sponsors and Collaborators
Universidade Federal do Rio de Janeiro
Investigators
Layout table for investigator information
Principal Investigator: Melanie Rodacki, Ph.D Universidade Federal do Rio de Janeiro
Study Director: Oliveira E.P José, Ph.D Universidade Federal do Rio de Janeiro
Study Director: Lenita Zajdenverg, Ph.D Universidade Federal do Rio de Janeiro
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Data/Documents: Study Protocol  This link exits the ClinicalTrials.gov site
Identifier: Ethical Committee Approval
The Brazilian Ethical Committee's (Institutional Review Board) consubstanced approval protocol can be seen on the link informed on Google drive: https://drive.google.com/file/d/1BKmHQ-74HGcJwFenAUcyzKnAxxYqqZ-h/view?usp=sharing

Layout table for additonal information
Responsible Party: Débora Lopes Souto, Ph. D. in Nutrition Sciences, Universidade Federal do Rio de Janeiro
ClinicalTrials.gov Identifier: NCT03920397     History of Changes
Other Study ID Numbers: Nutro_MesenchymalStemCells_DM1
First Posted: April 18, 2019    Key Record Dates
Last Update Posted: April 23, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Débora Lopes Souto, Universidade Federal do Rio de Janeiro:
type 1 diabetes
pancreatic function
adipose tissue-derived stromal/stem cells

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Cholecalciferol
 Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Vitamins
Micronutrients
Nutrients
Growth Substances
Bone Density Conservation Agents